echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > FDA shelved clinical plans to test lysergic acid diethylamine (LSD) for the treatment of generalized anxiety disorder (GAD)

    FDA shelved clinical plans to test lysergic acid diethylamine (LSD) for the treatment of generalized anxiety disorder (GAD)

    • Last Update: 2022-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Generalized Anxiety Disorder (GAD) is a state of constant anxiety about trivial matters.
    This anxiety has nothing to do with any specific surroundings, but is generally caused by excessive worry
    .


    There are four symptoms of generalized anxiety disorder: motor tension, nervous system overactivity, worry about the future, fear, and excessive alertness


    child

    Figure 1.
    The prevalence of GAD

    Biopharmaceutical company Mind Medicine recently revealed that the FDA has shelved a Phase IIb trial of lysergic acid diethylamine (LSD) for the treatment of generalized anxiety disorder (GAD)
    .


    The reason for this move is not yet clear, but the company said it expects to provide more details within 30 days


    Biopharmaceutical company Mind Medicine recently revealed that the FDA has shelved a Phase IIb trial of lysergic acid diethylamine (LSD) for the treatment of generalized anxiety disorder (GAD)


    The frustration of psychedelic adjuvant therapy

    The frustration of psychedelic adjuvant therapy

    This FDA move is the latest blow to the field of psychedelic adjuvant therapy
    .


    In November, due to safety issues with the experimental drug COMP360 of the pharmaceutical company COMPASS Pathways, the FDA held a negative attitude towards the drug


     

    Original source:

    Original source:

    https://firstwordpharma.


    https://firstwordpharma.
    com/story/5466469 https://firstwordpharma.
    com/story/5466469 Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.